Theratechnologies, Inc. (THTX) News

Theratechnologies, Inc. (THTX): $2.11

-0.03 (-1.40%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add THTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 507

in industry

Filter THTX News Items

THTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

THTX News Highlights

  • For THTX, its 30 day story count is now at 5.
  • Over the past 29 days, the trend for THTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • DRUG, MTD and SV are the most mentioned tickers in articles about THTX.

Latest THTX News From Around the Web

Below are the latest news stories about Theratechnologies Inc that investors may wish to consider to help them evaluate THTX as an investment opportunity.

Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update

- FY2021 consolidated sales grew 5.7% supported by strong EGRIFTA SV® sales - Second half fiscal 2021 revenues grew 10% over 2020, while total new enrollments grew 24% as commercial execution strategy firmly carries momentum into 2022 - Lead oncology asset TH1902 trial advances towards establishing MTD and initiation of larger Phase 1/Part B expansion (basket trial) - Company announces revenue guidance of US$79M to US$84M for Fiscal 2022 MONTREAL, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Theratechnolog

Yahoo | February 24, 2022

Theratechnologies Presents Results From Trogarzo® IV Push Administration Study at CROI 2022

No difference in pharmacokinetics between IV Push and IV InfusionNo serious adverse events observedNo difference in viral load between IV Push and IV Infusion and no anti-drug antibodies detected MONTREAL, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the presentation of positive results from the Phase 3

Yahoo | February 16, 2022

Theratechnologies Strengthens Global Commercial Capabilities by Launching Internal Field Force

- Top Performing U.S. Based Key Account Managers, Medical Sales Liaisons, and Community Liaisons to join Theratechnologies’ from its current partner contract sales organization - Higher employee engagement and retention, greater ability to attract top talent and lower turnover rate expected from the move MONTREAL, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and com

Yahoo | February 15, 2022

Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021

MONTREAL, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its fourth quarter of fiscal 2021 ended November 30, 2021 as well as for its full fiscal year 2021 on Thursday, February 24, 2022. A conference call will be held on February 24, 2022 at 8:30 a.m. (ET) to discuss the results and

Yahoo | February 10, 2022

Theratechnologies (TSE:TH) three-year losses have grown faster than shareholder returns have fallen, but the stock pops 11% this past week

This week we saw the Theratechnologies Inc. ( TSE:TH ) share price climb by 11%. But that doesn't change the fact that...

Yahoo | January 26, 2022

Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV

sBLA submission with FDA follows on the back of recently announced positive TMB-302 study resultsMONTREAL, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the submission of a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration (FDA) for the Company’s intravenous (IV) pu

Yahoo | December 6, 2021

Theratechnologies Named Recipient of the 2021 ADRIQ Innovation Award in the "Life Sciences" Category

MONTREAL, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it was awarded of the 2021 Innovation Award in the “Life Sciences” category at the 31st ADRIQ Innovation Awards Gala held on November 25, 2021. Every year, the ADRIQ (Association pour le développement de la recherche et de l'innovation du Québec

Yahoo | November 26, 2021

Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended

Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has filed a preliminary short form base shelf prospectus with the securities regulatory authorities of all the provinces of Canada and a corresponding shelf registration statement with the United States Securities and Exchange Commission (the "SEC") on Form F-10.

Yahoo | November 23, 2021

Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021

MONTREAL, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer, will present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021 at 9:40 a.m. ET. A live webcast of the event can be accessed through the investor relations section of Theratechnologies’

Yahoo | November 3, 2021

Theratechnologies Announces Reimbursement Agreement in Italy for Trogarzo® for Eligible Patients With Multi-Drug Resistant HIV-1

MONTREAL, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it has reached an agreement with the Italian Medicines Agency, AIFA, for the reimbursement of Trogarzo® for eligible people aged 18 and older living with multi-drug resistant (MDR) HIV-1. “This agreement is an important milestone for Trogarzo® and for HIV-1

Yahoo | October 26, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4687 seconds.